Results Earnings Call for Q2FY23 of Suven Pharmaceuticals
Conference Call with Suven Pharmaceuticals Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.10-11-2022
10-11-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and half-year ended September 30, 2022. The advertisements as appeared on November 9, 2022 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements10-11-2022
Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting-Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half-Year Ended 30Th September, 2022
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2022. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2022 2) Limited Review Reports on the financial results as mentioned above and 3) Earnings Presentation of our company to investors We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M. This is for your information and record.08-11-2022
Suven Pharmaceuticals Ltd - 543064 - Clarification /Confirmation On News Item Appearing In 'Media/Publication'
We refer to your email/letter cited under reference on the subject received through email, asking us clarify on the news item that appeared today in the 'Website-www.moneycontrol.com' dated November 04, 2022 captioned 'Blackstone, Advent International in talks to buy controlling stake in Suven Pharma: Report.'04-11-2022
Suven Pharmaceuticals Ltd - 543064 - Clarification sought from Suven Pharmaceuticals Ltd
The Exchange has sought clarification from Suven Pharmaceuticals Ltd on November 4, 2022, with reference to news appeared inhttps://www.moneycontrol.com/ dated November 4, 2022 quoting "Blackstone, Advent International in talks to buy controlling stake in Suven Pharma: Report"The reply is awaited.04-11-2022
Blackstone, Advent in talks to buy stake in Suven Pharma
Advent has been lapping up pharma firms in the past two years, but for Blackstone, this is its first bid to buy a pharma company04-11-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Wednesday, November 9, 2022 at 12:00 Noon IST to discuss the Un-Audited Financial Results for the Q2 & H1 FY23, to be declared on November 8, 2022.03-11-2022
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs03-11-2022
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Tuesday, The November 8, 2022
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Tuesday, the November 8, 2022 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No. 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the second quarter and half-year ending September 30, 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st October, 2022 as per PIT Code of the Company. Trading window will be opened from 12th November, 2022.01-11-2022
Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- K HANUMANTHA RAODesignation :- Company Secretary and Compliance Officer20-10-2022